**BMJ Open**

Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe)

Christel Häggström, Fredrik Liedberg, Oskar Hagberg, Firas Aljabery, Viveka Ströck, Abolfazl Hosseini, Truls Gårdmark, Amir Sherif, Per-Uno Malmström, Hans Garmo, Staffan Jahnson, Lars Holmberg

**ABSTRACT**

**Purpose** To monitor the quality of bladder cancer care, the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997. During 2015, in order to study trends in incidence, effects of treatment and survival of men and women with bladder cancer, we linked the SNRUBC to other national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe).

**Participants** The SNRUBC is a nationwide register with detailed information on 97% of bladder cancer cases in Sweden as compared with the Swedish Cancer Register. Participants in the SNRUBC have registered data on tumour characteristics at diagnosis, and for 98% of these treatment data have been captured. From 2009, the SNRUBC holds data on 88% of eligible participants for follow-up 5 years after diagnosis of non-muscle invasive bladder cancer, and from 2011, data on surgery details and complications for 85% of participants treated with radical cystectomy. The BladderBaSe includes all data in the SNRUBC from 1997 to 2014, and additional covariates and follow-up data from linked national register sources on comorbidity, socioeconomic factors, detailed information on readmissions and treatment side effects, and causes of death.

**Findings to date** Studies based on data in the SNRUBC have shown inequalities in survival and treatment indication by gender, regions and hospital volume. The BladderBaSe includes 38 658 participants registered in SNRUBC with bladder cancer diagnosed from 1 January 1997 to 31 December 2014. The BladderBaSe initiators are currently in collaboration with researchers from the SNRUBC investigating different aspects of bladder cancer survival.

**Future plans** The SNRUBC and the BladderBaSe project are open for collaborations with national and international research teams. Collaborators can submit proposals for studies and study files can be uploaded to servers for remote access and analysis. For more information, please contact the corresponding author.

**Strengths and limitations of this study**

- The Swedish National Register of Urinary Bladder Cancer (SNRUBC) is used for monitoring the quality of care of bladder cancer and has captured data on 97% of bladder cancer cases in Sweden in the period 1997–2014. We linked data in the SNRUBC to national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe).
- To our knowledge, with 38 658 cases based on an unselected population with very high coverage from an entire nation, BladderBaSe forms the largest and most comprehensive clinical bladder cancer database.
- In addition to bladder cancer tumour characteristics and treatment, the BladderBaSe includes information on comorbidity, socioeconomic factors, detailed information on readmissions and treatment side effects, and causes of death.
- We have no information or systematic evaluation of the 3% with bladder cancer not registered in the SNRUBC and no validation studies of the data in the SNRUBC against individual patient records.

**INTRODUCTION**

Bladder cancer imposes an important health problem worldwide; it is the fourth most common cancer among men in developed countries, with no improvement in survival over the last decades, in addition to a high cost of treatment on a per-patient basis. The Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997 to register all new cases of bladder cancer with detailed information on tumour location, size and extension (tumour, node, metastases classification of malignant tumours), grade, and primary treatment. The SNRUBC registration expanded in 2009 to register data from 5-year follow-up of non-muscle invasive bladder cancer, and...
in 2011 to register data on radical cystectomy. The main aim of the SNRUBC is quality assurance of bladder cancer healthcare; a secondary aim is to use the data for clinical research. Examples of quality indicators monitored by the SNRUBC are lead times and proportions of patients seen at multidisciplinary conferences. The SNRUBC is administered by the Regional Cancer Centre (RCC) in each of the six healthcare regions in Sweden and collated to a national register.

In 2015, we linked the SNRUBC to a number of national healthcare and demographic registers to construct the Bladder Cancer Data Base Sweden (BladderBaSe). The aim was to create a comprehensive cohort of patients with bladder cancer to study trends in incidence, effects of treatment, and overall as well as disease-specific survival, with detailed data on patient and tumour characteristics, treatment, socioeconomic factors and comorbidity.

**COHORT DESCRIPTION**

**Swedish National Register of Urinary Bladder Cancer**

In Sweden, new histologically, cytologically or clinically diagnosed tumours are mandated by law to be reported to the national Swedish Cancer Registry. All new diagnoses of a tumour in the bladder with International Classification of Diseases for Oncology, 3rd revision (ICD-O-3) code C67.0–C67.6 and C67.8–C67.9 for individuals 18 years or older are additionally requested to be reported into the SNRUBC. Data are collected by the six RCCs, which report to the national databases for the Swedish Cancer Registry and the SNRUBC. The records are validated and checked for completeness by each RCC. In the period 1997–2014 the coverage of bladder cancer cases in the SNRUBC was 97% as compared with the Swedish Cancer Register with regional variation from 92% to 100% (figure 1).

Patient records in the SNRUBC are standardised into four forms with data on (1) characteristics of the primary tumour at diagnosis; (2) primary treatment; (3) follow-up at 5 years after diagnosis for non-muscle invasive bladder cancer; and (4) preoperative, perioperative and postoperative events in conjunction with radical cystectomy. The number of participants and the coverage of the four registration forms in the SNRUBC from 1997 to 2014 are shown in figure 2. In short, all participants have registered data on diagnosis, and of these 98% have data on treatment; of the eligible participants with non-muscle invasive bladder cancer, 88% have data on 5-year follow-up, and of eligible participants treated with radical cystectomy 85% have registered details of the surgery, complications and reoperations.

The forms for tumour information at diagnosis and treatment have been in use since the initiation in 1 January 1997. From 1 January 2009, participants with non-muscle invasive bladder cancer (stage Ta, Tis or T1) without metastases are registered with data on time to relapse, progress and death 5 years after date of diagnosis (ie, for participants with year of diagnosis 2004 and forward). From 1 January 2011, detailed data on radical cystectomy are registered with surgical details, complications and reoperations up to 90 days postoperatively according to the Clavien-Dindo classification of surgical complications.

An overview of variables registered in the four standardised registration forms in the SNRUBC is listed in table 1. Detailed information on variables and captured ratios from 1997 to 2014 in the four forms are shown in online supplementary tables 1–4. In addition, the radical cystectomy form includes data on complications and reoperations within 90 days of the surgery, shown in online supplementary table 5.

**Bladder Cancer Data Base Sweden**

In 2015, data on participants in the SNRUBC with date of registration from 1 January 1997 to 31 December 2014 were linked to a number of healthcare and demographic registries at the National Board of Health and Welfare and the Statistics Sweden by use of the personal identification number (PIN) to form the BladderBaSe (figure 3). The PIN is a unique 10-digit number assigned to each individual in the Swedish population, and allows for virtually 100% coverage in the Swedish healthcare system. Participants in the BladderBaSe have been assigned an internal identification (ID) number, for which the key between the PIN and internal ID number is kept exclusively by Statistics Sweden. Participants with no date of diagnosis or less than 18 years of age at date of diagnosis were excluded. Last day of follow-up for participants in the BladderBaSe was date of death, date of emigration or 31 December 2014, whichever happened first.

The BladderBaSe includes information from 28 814 men and 9844 women with bladder cancer. Baseline characteristics of participants registered and lost to follow-up in the four standardised registration forms in the SNRUBC are shown in online supplementary table 6. An overview of variables retrieved from each register is shown in table 2. More details of each register and selected variables are described below.

**The Patient Register**

The Swedish Patient Register is administered by the National Board of Health and Welfare and includes nationwide information regarding inpatient and outpatient care from 1987. Each record holds dates of admission and discharge, hospital unit, procedures and diagnoses coded according to the ICD-9 or ICD-10. The Charlson Comorbidity Index (CCI) was calculated with data from the Patient Register to estimate the concomitant disease burden of the participants in BladderBaSe. The CCI is based on a list of diseases with a specific weight assigned to each disease category. The separate weights are collated to an overall score, categorised into 0 for no comorbidity, 1 for mild comorbidity, 2 for intermediate and 3 or more for severe comorbidity. For participants with metastatic bladder cancer at date of diagnosis, data on metastatic cancer was not included in
the calculations of CCI. A validation study of the Patient Register reported high validity for most diagnoses, with a positive predictive value of 85%–95%. Furthermore, data were retrieved both prior to and after the date of bladder cancer diagnosis from the Patient Register on risk factors for bladder cancer, risk factors of treatment side effects, and/or modifiers of treatment response and natural history of the disease. Examples of such data are urinary tract infections, type 2 diabetes mellitus, chronic obstructive pulmonary disease and prior abdominal or pelvic surgery.

**The Cancer Register**
The Swedish Cancer Register was initiated 1958 and has due to mandatory reporting high validity. We retrieved data on all other cancer diagnoses and their dates.
**Figure 2** Flow diagram of data collected in the Swedish National Register of Urinary Bladder Cancer (SNRUBC), with number of participants and capture rates from 1997 to 2014.

**Table 1** Overview of data included in the four standardised forms in the Swedish National Register of Urinary Bladder Cancer

| Registration form | Data recorded |
|-------------------|---------------|
| **Tumour characteristics at diagnosis** | Reporter information: hospital and department  
Tumour information: TNM stage, grade, tumour diameter, number of tumours, histology and morphological codes  
Dates of: diagnosis, referral, received referral, first visit to specialist and TUR/px  
Alternatives for referral reason and morphological confirmation |
| **Treatment** | Reporter information: hospital and department  
Primary investigation options: data on multidisciplinary conference, single-dose chemotherapy and resection  
Date and details of given treatment: intravesical instillations, systemic chemotherapy, radical cystectomy, radiotherapy or other treatments |
| **Five-year follow-up for non-muscle invasive bladder cancer** | Reporter information: hospital and department  
Status and date of recurrence and progression |
| **Radical cystectomy** | Reporter information: hospital and department  
Preoperative data: TNM stage, weight, height, body mass index, American Society of Anesthesiologists score, previous pelvic surgery, radiation or neoadjuvant chemotherapy  
Perioperative data: type of surgery, type of lymphadenectomy, type of urinary diversion, blood loss, duration of surgery, accidental organ injury during surgery  
Postoperative data: complications, reoperations and readmissions within 90 days, length of hospital stay, pathological T stage, number of excised lymph nodes, and number of excised and metastatic lymph nodes |

TNM, tumour, node, metastases; TUR/px, transurethral resection.
irrespective of date of bladder cancer diagnosis for all participants in the BladderBaSe.

**The Causes of Death Register**
From the Causes of Death Register we retrieved data on underlying and contributing causes of death and dates of death. The Causes of Death Register was initiated in 1953, and the proportion of missing death certificates in 2014 was 1%. 14

**Swedish Household Census and the Register of Total Population and Population Changes**
From the Statistics Sweden we retrieved data from the Register of Total Population and Population Changes and the Swedish Household Census on marital status, country of birth, dates of immigration and emigration. 15 Furthermore, we retrieved data from the Swedish Household Census from year 1990 on socioeconomic status based on the Swedish Socio-Economic Index and profession.

**Longitudinal Integration Database for Health Insurance and Labour Market Studies**
The Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA) database administered by the Statistics Sweden holds annual registers from 1990 of data based on the labour market, educational and social sectors. The LISA database has information at an individual level, and at group level such as families, companies and places of employment. From the LISA database we retrieved information about socioeconomic ...
variables such as educational level, profession, annual family and individual income.

Findings to date

A list of publications based on the SNRUBC is shown in online supplementary table 7. The SNRUBC steering committee has published annual reports online, and from 2011 separate reports for radical cystectomy. In the SNRUBC, female gender has been associated with more aggressive tumours, less probability of optimal treatment and shorter survival, in comparison to men.

Time trends over 15 years in SNRUBC revealed a rising mean age at diagnosis, a larger proportion of non-muscle invasive tumours and no improvement of survival. Studies on muscle invasive bladder cancer showed that curative treatment was less likely to be given at low-volume as compared with high-volume hospitals, for female gender as compared with male gender, and for older patients as compared with younger. Studies on non-muscle invasive bladder cancer showed large regional variations of disease progression 5 years after diagnosis, an underuse

---

**Table 3  Descriptive statistics at date of diagnosis of participants included in the Bladder Cancer Data Base Sweden (BladderBaSe)**

|                          | Men (n=28 814) | Women (n=9844) |
|--------------------------|----------------|----------------|
|                          | N   | %   | N   | %   |
| **Year of diagnosis**    |     |     |     |     |
| 1 January 1997 to 31 December 2002 | 8610 | 30  | 3062 | 31  |
| 1 January 2003 to 31 December 2008 | 9405 | 33  | 3138 | 32  |
| 1 January 2009 to 31 December 2014 | 10 799 | 37  | 3644 | 37  |
| **Type of bladder cancer** |     |     |     |     |
| Non-muscle invasive       | 21 330 | 74  | 6734 | 68  |
| Muscle invasive           | 6920 | 24  | 2891 | 29  |
| T stage X or missing      | 564 | 2   | 219  | 2   |
| **Age at diagnosis**      |     |     |     |     |
| Less than 65 years        | 6653 | 23  | 2306 | 23  |
| 65–69 years               | 4257 | 15  | 1272 | 13  |
| 70–74 years               | 5110 | 18  | 1412 | 14  |
| 75–79 years               | 5227 | 18  | 1734 | 18  |
| 80–84 years               | 4349 | 15  | 1600 | 16  |
| 85 years and above        | 3218 | 11  | 1520 | 15  |
| **Marital status**        |     |     |     |     |
| Married                   | 18 118 | 63  | 3888 | 39  |
| Divorced                  | 3959 | 14  | 1593 | 16  |
| Unmarried                 | 2859 | 10  | 904  | 9   |
| Widowed                   | 3570 | 12  | 3383 | 34  |
| Missing                   | 308  | 1   | 76   | 1   |
| **Education level**       |     |     |     |     |
| Low                       | 12 944 | 45  | 4641 | 47  |
| Intermediate              | 10 118 | 35  | 3286 | 33  |
| High                      | 4833 | 17  | 1467 | 15  |
| Missing                   | 919  | 3   | 450  | 5   |
| **Charlson Comorbidity Index prior to diagnosis** |     |     |     |     |
| No comorbidity (0)        | 16 274 | 56  | 6413 | 65  |
| Mild comorbidity (1)      | 5034 | 17  | 1549 | 16  |
| Intermediate comorbidity (2) | 4154 | 14  | 1066 | 11  |
| Severe comorbidity (3 or more) | 3352 | 12  | 816  | 8   |

*Educational level categorised as low (≤9 years of school), intermediate (10–12 years) and high (≥13 years), corresponding to mandatory school, high school and college or university.
†Charlson Comorbidity Index is calculated during a 10-year period prior to diagnosis. Comorbidity scores for metastatic cancer are not included in the Charlson Comorbidity Index for participants with metastatic bladder cancer at date of diagnosis.
of bacillus Calmette–Guérin (BCG) for stage T1 bladder cancer, and large regional variations in treatment of stage Ta and T1 bladder cancer. Studies on radical cystectomy have shown high risk of complications within 90 days for long surgery duration and higher patient age, and a higher reoperation rate for patients receiving a continent diversion as compared with an ileal conduit. Moreover, patients treated with radical cystectomy at high-volume hospitals had longer survival and lower risk of local recurrence as compared with patients treated at low-volume hospitals, and university hospitals more often used continent reconstruction as urinary diversion after radical cystectomy as compared with county hospitals, but with regional variations.

In BladderBaSe, 24% of male and 29% of the female participants were diagnosed with muscle invasive bladder cancer. Tabulated information of other variables at diagnosis is shown in table 3. Data on education level and marital status were retrieved at date of diagnosis, and data on CCI were calculated based on data from 10 years’ time prior to date of diagnosis. The BladderBaSe project group in collaboration with researchers from the SNRUBC is currently investigating survival after a diagnosis of muscle invasive bladder cancer, readmissions and side effects after radical cystectomy, temporal and regional trends of treatment, and survival for non-muscle invasive bladder cancer.

STRENGTHS AND LIMITATIONS
To our knowledge, with 38 658 cases based on an unselected population in a register with very high coverage from an entire nation, BladderBaSe forms the largest clinical bladder cancer database. The main strengths of the BladderBaSe are detailed information on tumour characteristics, treatments and follow-up, and in addition data on important confounding factors such as socioeconomic variables and comorbidity. The main weaknesses are the lacking information on the 3% with bladder cancer not registered in the SNRUBC and no validation studies of the data in the SNRUBC against individual patient records.

COLLABORATION
The steering group of the SNRUBC and the project group working with the BladderBaSe are open for collaboration with national and international research teams. Collaborators can propose and apply for studies in the BladderBaSe using a standardised form. After approved application, the project data administrators upload study-specific files with selected variables to a server for statistical analysis through remote access. Users of this system will be charged for software licences, data administration and for preprocessing of study files.

Studies within the aim of the BladderBaSe as stated in the introduction have approval from Research Ethics Board and included registries. Collaborators who wish to study other objectives need to apply to the Research Ethics Board. When reporting studies from BladderBaSe, authors are encouraged to use the STrengthening the Reporting of Observational studies in Epidemiology (STROBE) checklist for cohort studies. For more information of collaboration with the SNRUBC or the BladderBaSe, contact the corresponding author (CH), email: christel.haggstrom@umu.se.

Author affiliations
1Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
2Department of Biobank Research, Umeå University, Umeå, Sweden
3Department of Urology, Skåne University Hospital, Malmö, Sweden
4Department of Translational Medicine, Lund University, Malmö, Sweden
5Regional Cancer Centre South, Lund, Sweden
6Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden
7Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
8Department of Urology, Karolinska University Hospital, Stockholm, Sweden
9Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden
10Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
11Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
12Regional Cancer Centre Uppsala/Orebro, Uppsala, Sweden
13Department of Clinical Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK
14Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
15Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden
16Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
17Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
18Regional Cancer Centre Uppsala/Orebro, Uppsala, Sweden
19Regional Cancer Centre Uppsala/Orebro, Uppsala, Sweden
20Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
21Department of Biobank Research, Umeå University, Umeå, Sweden
22Department of Urology, Skåne University Hospital, Malmö, Sweden
23Department of Translational Medicine, Lund University, Malmö, Sweden
24Regional Cancer Centre South, Lund, Sweden
25Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden
26Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
27Department of Urology, Karolinska University Hospital, Stockholm, Sweden
28Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden
29Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
30Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
31Regional Cancer Centre Uppsala/Orebro, Uppsala, Sweden
32Regional Cancer Centre Uppsala/Orebro, Uppsala, Sweden
33Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
34Department of Biobank Research, Umeå University, Umeå, Sweden
35Department of Urology, Skåne University Hospital, Malmö, Sweden
36Department of Translational Medicine, Lund University, Malmö, Sweden
37Regional Cancer Centre South, Lund, Sweden
38Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden
39Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
40Department of Urology, Karolinska University Hospital, Stockholm, Sweden
41Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden
42Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
43Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
44Regional Cancer Centre Uppsala/Orebro, Uppsala, Sweden
45Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
46Department of Biobank Research, Umeå University, Umeå, Sweden
47Department of Urology, Skåne University Hospital, Malmö, Sweden
48Department of Translational Medicine, Lund University, Malmö, Sweden
49Regional Cancer Centre South, Lund, Sweden
50Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden
51Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
52Department of Urology, Karolinska University Hospital, Stockholm, Sweden
53Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden
54Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
55Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
56Regional Cancer Centre Uppsala/Orebro, Uppsala, Sweden
57Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
58Department of Biobank Research, Umeå University, Umeå, Sweden
59Department of Urology, Skåne University Hospital, Malmö, Sweden
60Department of Translational Medicine, Lund University, Malmö, Sweden
61Regional Cancer Centre South, Lund, Sweden
62Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden
63Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
64Department of Urology, Karolinska University Hospital, Stockholm, Sweden
65Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden
66Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
67Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
68Regional Cancer Centre Uppsala/Orebro, Uppsala, Sweden
69Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
70Department of Biobank Research, Umeå University, Umeå, Sweden
71Department of Urology, Skåne University Hospital, Malmö, Sweden
72Department of Translational Medicine, Lund University, Malmö, Sweden
73Regional Cancer Centre South, Lund, Sweden
74Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden
75Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
76Department of Urology, Karolinska University Hospital, Stockholm, Sweden
77Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden
78Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
79Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
80Regional Cancer Centre Uppsala/Orebro, Uppsala, Sweden

Acknowledgements This project was made possible with help of the data collected in the SNRUBC, and we would like to thank the members of the SNRUBC: VS, FA, Johan Johansson, P-UM, Malcolm Carringer, AH, TG, AS, Roland Rux, Markus Johansson, Petter Kolberg, Anna-Karin Lind, Jenny Wanegård, Magdalena Cwikiel, Elisabeth Överholm, Anders Ullen, Erika Jonsson, Helena Thulin, Gun Danielsson, Helene Hummer, Fredrik Lidberg, and SJ. We also thank Pär Stattin for guidance with database administration.

Contributors CH, FL, SJ and LH initiated the study and drafted the manuscript. FL, FA, VS, AH, TG, AS, P-UM and SJ contributed with data, and CH, OH and HG analysed data. All authors revised the manuscript and approved the final version to be published.

Funding This work was supported by the Swedish Cancer Society, grant number CAN 2013/472.

Competing interests None declared.

Ethics approval This study was approved by the Research Ethics Board at Uppsala University, Sweden.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Annual reports from the SNRUBC are available online at http://www.cancercentrum.se/vast/cancerdiagnoser/uninagar/unibrase-och-unirvags cancer/kvalitetsregister/. Collaborators can propose and apply for studies in the BladderBaSe using a standardised form. After approved application, the project data administrators can upload study-specific files with selected variables to a server for statistical analysis through remote access. Users of this system will be charged for software licences, data administration and for preprocessing of study files. For more information contact the corresponding author.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
2. Bryan RT, Kirby R, O’Brien T, et al. So much cost, such little progress. *Eur Urol* 2014;66:263–4.

3. Jahnson S, Hosseini Aliabad A, Holmäng S, et al. Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment. *Scand J Urol* 2016;50:14–20.

4. Kaplan AL, Litwin MS, Chamie K, et al. The future of bladder cancer care in the USA. *Nat Rev Urol* 2014;11:59–62.

5. The National Board of Health and Welfare. National Cancer Register. 2015 http://www.socialstyrelsen.se/register/halsodateregister/cancerregistret

6. Regionala Cancercentrum i Samverkan. Nationellt kvalitetsregister för urinblåsecancer. Nationell Rapport Blåscancerregistret, 2015 http://www.cancercentrum.se/vast/cancerdiagnoser/urinvag/var/urinblaseoch-urinvagscancer/kvalitetsregister/

7. Regionala Cancercentrum i Samverkan. Nationellt kvalitetsregister för urinblåsecancer. Nationell Rapport Cystektomiregistret, 2014 http://www.cancercentrum.se/vast/cancerdiagnoser/urinvag/var/urinblaseoch-urinvagscancer/kvalitetsregister/

8. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205–13.

9. Ludvigsson JF, Otterblad-Olausson P, Petersson BU, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. *Eur J Epidemiol* 2009;24:659–67.

10. The National Board of Health and Welfare. The National Patient Register, 2015 http://www.socialstyrelsen.se/register/halsodateregister/patientregistret

11. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–83.

12. Ludvigsson JF, Andersson E, Ekbohm A, et al. External review and validation of the Swedish national inpatient register. *BMC Public Health* 2011;11:450.

13. Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. *Acta Oncol* 2009;48:27–33.

14. The National Board of Health and Welfare. Causes of Death, 2014 http://www.socialstyrelsen.se/publikationer2015/2015-8-1

15. Ludvigsson JF, Almqvist C, Bonamy AK, et al. Registers of the Swedish total population and their use in medical research. *Eur J Epidemiol* 2016;31:125–36.

16. Thorstenson A, Hagberg O, Ljungberg B, et al. Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. *Scand J Urol* 2016;50:292–7.

17. Jahnson S, Damm O, Hellsten S, et al. A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. *Scand J Urol Nephrol* 2009;43:271–6.

18. Liedberg F, Hagberg O, Holmäng S, et al. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. *Scand J Urol* 2015;49:290–5.

19. Patschan O, Holmäng S, Hosseini A, et al. Use of bacillus Calmette-Guérin in stage T1 bladder cancer: Long-term observation of a population-based cohort. *Scand J Urol* 2015;49:127–32.

20. Gårdmark T, Bladström A, Hellsten S, et al. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. *Scand J Urol Nephrol* 2006;40:276–82.

21. Jerlström T, Gårdmark T, Carringer M, et al. Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database. *Scand J Urol* 2014;48:334–40.

22. Sabir EF, Holmäng S, Liedberg F, et al. Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. *Scand J Urol* 2013;47:483–90.

23. Liedberg F, Holmberg E, Holmäng S, et al. Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey. *Scand J Urol Nephrol* 2012;46:14–18.

24. Jahnson S, Damm O, Hellsten S, et al. Urinary diversion after cystectomy for bladder cancer: a population-based study in Sweden. *Scand J Urol Nephrol* 2010;44:69–75.